Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells

  • The PLOS ONE Staff

S1 Table is omitted from the list of Supporting Information. It can be viewed below.

S1 File is also omitted from the list of Supporting Information. It can be viewed below.

The publisher apologizes for the errors.

Supporting information

S1 Table. Summary of inhibitors used in this study and the corresponding cellular transporters upon which they act.

https://doi.org/10.1371/journal.pone.0203583.s001

(DOCX)

S1 File. Supplementary methods.

https://doi.org/10.1371/journal.pone.0203583.s002

(DOCX)

Reference

  1. 1. Eadie LN, Dang P, Goyne JM, Hughes TP, White DL (2018) ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLoS ONE 13(1): e0192180. https://doi.org/10.1371/journal.pone.0192180pmid:29385210

Citation: The PLOS ONE Staff (2018) Correction: ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLoS ONE 13(8): e0203583. https://doi.org/10.1371/journal.pone.0203583

Published: August 31, 2018

Copyright: © 2018 The PLOS ONE Staff. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.